MBX Biosciences Valuation Multiples

MBX Biosciences Overview

About MBX Biosciences

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.

Founded

2018

HQ

Employees

43

Website

mbxbio.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

EBITDA: ($109M)

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

MBX Biosciences Financials

MBX Biosciences reported last 12-month revenue of — and negative EBITDA of ($109M).

In the same LTM period, MBX Biosciences generated ($81K) in gross profit, ($109M) in EBITDA losses, and had net loss of ($98M).

MBX Biosciences P&L

In the most recent fiscal year, MBX Biosciences reported revenue of — and EBITDA of ($98M).

MBX Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

MBX Biosciences Stock Performance

MBX Biosciences has current market cap of $1B, and enterprise value of $1B.

MBX Biosciences' stock price is $31.26.

MBX Biosciences Valuation Multiples

MBX Biosciences trades at (9.3x) EV/EBITDA.

MBX Biosciences Financial Valuation Multiples

As of March 21, 2026, MBX Biosciences has market cap of $1B and EV of $1B.

Equity research analysts estimate MBX Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

MBX Biosciences has a P/E ratio of (14.3x).

MBX Biosciences Margins & Growth Rates

MBX Biosciences' revenue in the last fiscal year grew by —.

MBX Biosciences' revenue per employee in the last FY averaged $0.0M.

MBX Biosciences Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

MBX Biosciences M&A Activity

MBX Biosciences acquired XXX companies to date.

Last acquisition by MBX Biosciences was on XXXXXXXX, XXXXX. MBX Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

MBX Biosciences Investment Activity

MBX Biosciences invested in XXX companies to date.

MBX Biosciences made its latest investment on XXXXXXXX, XXXXX. MBX Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).